Delivery Order SPE2DB20D2104-SPE2DB25FMXPC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $2,702.16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a contract ceiling value of $1,727.65. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by August 8, 2025. The award represents a routine pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $24,188.72. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 16, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a common medication used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $11,771.03, is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procedures with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $1,192.79 and a completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical will be supplied from the vendor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,374.62 to AmerisourceBergen Drug Corp for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg. This non-competitive delivery order, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price pharmaceutical procurement contract. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a $9,621.08 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. This contract is structured as a firm fixed price delivery order with an ultimate completion date of September 17, 2025, and represents a non-set-aside competitive award. The pharmaceutical will be supplied from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. The contract was awarded on August 12, 2025, under a firm fixed-price delivery order structure with a ceiling value of $1,601.60 and an ultimate completion date of August 13, 2025. This non-set-aside award was competitively procured and will be performed at AmerisourceBergen's headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. The contract, awarded on August 18, 2025, carries a ceiling value of $2,029.15 with a firm fixed price structure and an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This was a competitively awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $3,956.07 and an ultimate completion date of October 17, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXPCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg at a ceiling value of $3,011.99. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, representing a routine pharmaceutical procurement for federal medical supply needs. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive pharmaceutical support vehicle enabling the company to supply medications and medical supplies to support military healthcare programs globally. Tamsulosin HCL, a commonly used urological medication, is consistent with the therapeutic range of products AmerisourceBergen supplies through its DLA relationship to support Defense Health Agency and other federal healthcare system customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 8/12/25 |